Melanoma Stage III

Oncology
5
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
5
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Monoclonal Antibody
150%
+ 3 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
1 program
1
BNT111Phase 21 trial
Active Trials
NCT04526899Completed184Est. Nov 2025
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
1
Encorafenib + BinimetinibPhase 2Small Molecule1 trial
Active Trials
NCT05767879UnknownEst. Jan 2026
Philogen
PhilogenItaly - Monteriggioni
1 program
1
L19IL2Phase 2
Bristol Myers Squibb
1 program
1
NivolumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT06295159Recruiting90Est. Nov 2028
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
T-VECPhase 22 trials
Active Trials
NCT04330430Completed24Est. Jan 2025
NCT04427306Suspended6Est. May 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Bristol Myers SquibbNivolumab
Pierre FabreEncorafenib + Binimetinib
RegeneronBNT111
AmgenT-VEC
AmgenT-VEC

Clinical Trials (5)

Total enrollment: 304 patients across 5 trials

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Start: May 2024Est. completion: Nov 202890 patients
Phase 2Recruiting
NCT05767879Pierre FabreEncorafenib + Binimetinib

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Start: Jan 2022Est. completion: Jan 2026
Phase 2Unknown

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

Start: May 2021Est. completion: Nov 2025184 patients
Phase 2Completed

Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease

Start: Sep 2020Est. completion: Jan 202524 patients
Phase 2Completed

Neoadjuvant T-VEC in High Risk Early Melanoma

Start: May 2020Est. completion: May 20246 patients
Phase 2Suspended

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 304 patients
5 companies competing in this space